Inflammatory Bowel Disease

A Phase I clinical trial has begun evaluating Direct Biologics’ ExoFlo for the treatment of patients with medically refractory ulcerative colitis (UC). Direct Biologics uses extracellular vesicles (EVs) derived from bone marrow mesenchymal stem cells (MSCs) to address multiple disease indications. The trial is expected to enrol 10 patients, aged 18-75 years, who have had […]

Celltrion USA has submitted a Biologics License Application (BLA) under the 351 (a) pathway of the Public Health Service Act for CT-P13 SC for the treatment of inflammatory bowel disease (IBD).  The submission is based on results from the Phase III pivotal data that evaluated the efficacy and safety of CT-P13 SC as maintenance therapy […]

Jenny Bailey, CEO of Ferryx tells Lu Rahman how its leading product FX856 came to life and how it’s a game-changer for inflammatory bowel disease since it can act during active inflammation.  Ferryx is an innovative bio-tech start-up. It is a University of Bristol spin-out with a focus on gut health and IBD in particular. Its mission is to […]

Genetic Analysis (GA) has announced that the Norwegian Research Council has approved its grant application of NOK 16 million (€1.6 million) for its project developing new innovative microbiome-based diagnostics to be used to aid selection and treatment of Inflammatory Bowel Disease (IBD) patients. In this project, GA will develop an easy to use, in vitro […]